Curetis Announces Participation in Clinical, Scientific and Investor Meetings in the Third Quarter 2016
(Thomson Reuters ONE) -
Curetis AG /
Curetis Announces Participation in Clinical, Scientific and Investor Meetings in
the Third Quarter 2016
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 01, 2016 -- Curetis
N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of
next-level molecular diagnostic solutions, today announced its participation in
major scientific and investor meetings in the third quarter of 2016.
July-August:
AACC Annual Meeting & Clinical Lab Expo 2016, July 31 - August 04, 2016, in
Philadelphia, PA, USA. Exhibition booth no. 135.
September:
35th Annual Meeting of the European Bone & Joint Infections Society, September
1-3, 2016, in Oxford, UK. Exhibition booth no. E05. Joint meeting with Curetis'
partner Heraeus Medical.
68th Annual Meeting of the German Society for Hygiene and Microbiology (DGHM),
September 11-14, 2016, in Ulm, Germany. Exhibition booth details to be
confirmed. In addition, Curetis will host a Lunch Symposium.
Rodman & Renshaw 18th Annual Healthcare Conference 2016 New York, September
11-13, 2016, in New York, NY, USA. Company Presentation and One-on-One Meetings.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the
development and commercialization of reliable, fast and cost-effective products
for diagnosing severe infectious diseases. The diagnostic solutions of Curetis
enable rapid multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or even weeks with
other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and
Euronext Brussels and private equity funds of over EUR 63.5 million. The company
is based in Holzgerlingen near Stuttgart, Germany. Curetis has signed
collaboration agreements with Heraeus Medical and Cempra Inc. as well as several
international distribution agreements covering many countries across Europe, the
Middle East and Asia.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities
and neither this document nor any part of it should form the basis of any
investment decision in Curetis.
The information contained in this press release has been carefully prepared.
However, Curetis bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. Curetis does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information, future
events or for other reasons.
This press release includes statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements can be identified
by the use of forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or "should",
and include statements Curetis makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are not guarantees of future performance. Curetis' actual results may differ
materially from those predicted by the forward-looking statements. Curetis
undertakes no obligation to publicly update or revise forward-looking
statements, except as may be required by law.
For further information, please visit www.curetis.com.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr(at)curetis.com or ir(at)curetis.com
www.curetis.com - www.unyvero.com
International Media & Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info((at))akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor Inquiries
The Ruth Group
Lee Roth
lroth(at)theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo:
http://hugin.info/171382/R/2024407/752237.jpg
20160701_Curetis_PR_EN:
http://hugin.info/171382/R/2024407/752233.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Curetis AG via GlobeNewswire
[HUG#2024407]
Unternehmensinformation / Kurzprofil:
Datum: 01.07.2016 - 07:10 Uhr
Sprache: Deutsch
News-ID 481183
Anzahl Zeichen: 5541
contact information:
Town:
Holzgerlingen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 277 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Curetis Announces Participation in Clinical, Scientific and Investor Meetings in the Third Quarter 2016"
steht unter der journalistisch-redaktionellen Verantwortung von
Curetis AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
